Framed as a success, Soviet scientists synthesized alpha-2 interferon, expressed it in “E. coli,” and produced Reaferon. The story glosses over the elaborate technological background of scientific experiments.

Creating Soviet interferon went far beyond learning to make genes. It required the simultaneous mobilisation of scientists, research institutes, industrial organisations, pharmaceutical manufacturers, state agencies, fermentation equipment, biological materials, clinical facilities, and administrative structures. Only system integration turned the technology into a practical drug.

Hughes’s “Large Technological System” framework illuminates the process. Because systems rely on synchronized parts to function, system builders play a vital role by identifying problems, bridging disconnected elements, and forging relationships between them.

Technological systems also develop unevenly. A lagging “reverse salient” can block a system’s progress. System growth thus requires both invention and the constant resolution of critical problems. Through this lens, the Soviet recombinant interferon program was an exercise in system building. It highlights late Soviet biotech mobilization and scaling failures.

Academician Yurii Ovchinnikov was a key system builder linking molecular biology, industrial biotechnology, drug production, and state administration. Reaferon resulted from building a complex technological system, not a single breakthrough.

Launched in 1979 under Soviet bioorganic chemist Yurii Ovchinnikov, the Soviet recombinant interferon program sought to develop modern pharmaceuticals. The project quickly exceeded basic laboratory research. It brought together organisations belonging to different institutional and technological environments, most notably the USSR Academy of Sciences and the industrial biotechnology complex represented by Biopreparat.

One of the principal centres was Ovchinnikov’s Moscow-based M.M. Shemyakin Institute of Bioorganic Chemistry. Another was the All-Union Scientific-Research Institute of Molecular Biology (VNIIMB) at Kol’tsovo, part of the expanding Soviet biotechnology infrastructure. These institutions possessed different forms of expertise. The Shemyakin Institute specialised in chemical synthesis and molecular construction, while VNIIMB specialised in molecular biology and the biological expression of recombinant products.

This division of labor mirrors Hughes’s system framework. For Soviet scientists, synthesizing a gene was only part of the problem. A synthetic gene confined to a lab had little practical value. It required biological integration, production, purification, testing, fermentation, and a distribution infrastructure. Each element formed a core component of the emerging system.

Ovchinnikov’s influence bridged the deep Soviet divide between basic research and practical production. The Academy of Sciences, industrial ministries, medical institutions, and production organisations operated according to different administrative priorities. A discovery made within an academic institute did not automatically become an industrial technology. Moving from knowledge to production required organizational mediation.

In Hughes’s terms, it makes Ovchinnikov more than a leader. He can be understood as a “system builder.” His importance lay partly in his capacity to identify a technologically significant objective and mobilise the institutional components required to pursue it. His influence united organizations normally divided by administrative boundaries.

The programme consequently developed around two principal scientific groups. At the Shemyakin Institute, Academician Mikhail Nikolaevich Kolosov directed work concerned with the chemical synthesis and construction of the interferon gene. At VNIIMB, Professor Lev Stepanovich Sandakhchiev led research concerned with biological and molecular-biological aspects of the recombinant system. The division was an early form of “system integration,” uniting specialized expertise around a common goal.

By 1983, this network had produced a major scientific result. Kolosov and his colleagues reported in “Vestnik Akademii Nauk SSSR” the successful creation of an artificial gene coding for alpha-2 interferon that was functional in “Escherichia coli.” The achievement proved Soviet genetic engineering capabilities.

Yet from the perspective of technological-system history, the achievement was simultaneously a beginning and an incomplete accomplishment. The synthetic gene solved one of the programme’s critical problems, but it did not solve the problem of producing a pharmaceutical. The emerging system still required additional components.

Raymond Zilinskas’s account provides further details on the construction strategy. The synthetic gene lacked its first codon, allowing it to be joined to “E. coli” DNA during the cloning process. Using a tryptophan promoter allowed direct comparison with international research. Such details illustrate the international character of Soviet biotechnology. Although the programme was embedded within a Soviet institutional system, its researchers operated within an international technological environment in which experimental techniques, scientific publications, and competing achievements shaped the definition of technological progress.

The Soviet achievement therefore cannot be understood simply as an isolated demonstration of national scientific capability. It represented the successful connection of chemical synthesis, molecular biology, genetic engineering, and biological expression. Hughes viewed distinct parts as a system.

Gene construction alone did not create an industrial technology. The next problem was “scale.” Scientific proof versus viable production defines the Soviet program. Production yields had to be increased, genetic stability had to be maintained, degradation had to be controlled, and the biological product had to be recovered and purified at sufficient scale.

The All-Union Scientific-Research Institute of Genetics and Selection of Industrial Microorganisms (VNIIGenetika) illustrates this transition. Researchers enhanced yields, stability, and resistance.

Hughes’s “reverse salient” explains such problems. The synthetic gene itself had become a successful component of the technological system. Yet the production process remained comparatively underdeveloped. As the system advanced, hidden weaknesses became prominent. The reverse salient therefore shifted. At one stage, the central problem was:

Could Soviet scientists construct a functional synthetic interferon gene?

After the 1983 breakthrough, the question became:

Could that gene produce sufficient quantities of stable interferon?

Afterwards:

Could the product be purified?

Could it be manufactured consistently?

Could it satisfy medical standards?

Could it be tested clinically?

Could it be packaged and distributed?

The history of Reaferon is consequently a history of “successive reverse salients.” Solving one problem exposed the next. It helps explain why the programme required so many institutions. What might appear in retrospect as a single project was actually a chain of interdependent technological activities. The chain created ongoing requirements.

Such transition is clearest in Evgenii Sverdlov’s January 9, 1984 presentation. Reported by “Izvestiya” the next day, Sverdlov stressed recombinant technology’s potential to boost interferon supply.

He compared blood-derived production to recombinant methods. Sverdlov reported that one liter of donor blood yielded just one dose of interferon, while the same volume of bacterial culture could yield a thousand times more. He added that a Glavmikrobioprom plant produced five million doses in 1.5 shifts. Producing the same quantity from donor blood, he claimed, would have required twenty-five million donors.

The numbers illustrate the enormous technological promise of recombinant production. The technology mattered far beyond its technical sophistication. It potentially transformed the material basis of production. Interferon no longer had to depend upon the biological resources of human donors. Theoretically, a microbial system could transform genetic data into industrial pharmaceuticals.

Nevertheless, the historical record also reveals the difference between “technological possibility and technological stabilisation.” In March 1987, “Pravda” reported that the Ladyzhyn Plant produced only 50,000 interferon doses throughout 1986. The contrast with Sverdlov’s reported five million doses in one and a half shifts is striking.

Hughes explains such discrepancy. The five-million-dose figure may have represented an experimental or semi-industrial achievement under particular conditions rather than a sustainable routine production rate. The later figure suggests that the broader technological system had not necessarily acquired the capacity to reproduce that result consistently. The fermenter could function in isolation even if the overall system could not support continuous operation.

This distinction is crucial. A technological system is more than the sum of its successful experiments. It requires long-term component integration. Raw materials, equipment, personnel, maintenance, purification, quality control, administrative coordination, and distribution must all function together. A spectacular production run demonstrates possibility; a functioning industry demonstrates “system stability.”

Sverdlov himself acknowledged that the work was not yet complete. He described the programme as involving scientists and specialists from the D. I. Ivanovsky Institute of Virology, the N. F. Gamaleya Institute of Epidemiology and Microbiology, the Institute of Genetics and Selection of Industrial Microorganisms, the Institute of Technology of Blood Substitutes and Hormonal Preparations, and the Institute of Organic Synthesis of the Academy of Sciences of the Latvian SSR.

This list is almost a map of the emerging technological system. Each institution addressed a different component of the problem. Expanded ambitions forced the program to bridge molecular biology, industry, medicine, pharma, and chemistry, driving immense complexity.

Sverdlov’s trial, purification, and packaging discussions show recombinant interferon production hitting new reverse salients. The problem was no longer simply whether the technology worked. It was whether the resulting product could become a standardised pharmaceutical.

The recombinant alpha-2 interferon was named “Reaferon.” Before clinical evaluation, the preparation underwent preclinical trials at the Biopreparat Institute of Immunology in Lyubuchany, involving several other Soviet research organisations, including the N. F. Gamaleya Scientific-Research Institute of Epidemiology and Microbiology in Moscow, the Scientific-Research Institute of Biological Testing of Chemical Compounds at Staraya Kupavna, and the Scientific-Research Institute of Experimental Medicine in Sukhumi.

As the number of organizations grew, the problem shifted from a scientific one to a broader pharmaceutical one. Reaferon had to be not only biologically effective but also medically usable. It required new system components. Immunology was required to understand biological effects. Experimental medicine was necessary for preclinical evaluation. Pharmaceutical institutions managed formulation and quality standards. Clinical institutions would eventually assess the preparation in humans. Production facilities had to manufacture it at scale.

Thus, Reaferon’s development exemplifies what Hughes terms “system growth.” Technological systems grow not simply by adding more machines but by incorporating new forms of knowledge, organisation, infrastructure, and institutional authority. As the Soviet interferon program expanded, so did the definition of relevant expertise.

The story spans far beyond the Shemyakin Institute. The institute was indispensable to the original molecular breakthrough, but no single institution possessed the complete technological system required to turn that breakthrough into a pharmaceutical.

The programme’s institutional complexity was therefore not evidence of inefficiency alone. It also resulted from technological maturity. As the technology became more ambitious, its system boundaries expanded. Vilnius’s 1990 alpha-2 production launch marked the system’s industrial maturity. Using a 1,000-liter fermenter, the institute’s pilot plant produced roughly one million doses. Shipped to Kaunas for packaging.

Its significance lay in integrating multiple technologies. The fermenter provided the physical infrastructure for biological production. The institute supplied technical and organisational expertise. The pharmaceutical facilities in Kaunas provided packaging capabilities. Together, these components transformed recombinant interferon from a laboratory product into something approaching an industrial commodity.

This was therefore more than an increase in production volume. It represented a significant degree of “system integration.” Institute management reportedly believed the technology could soon supply the entire Soviet market. Such confidence indicates the system was ready for further expansion.

Yet the historical timing of this achievement is profoundly important. The first major series production began in 1990, just as the Soviet system collapsed. The recombinant interferon program reached technological maturity just as its institutional environment faltered.

Hughes’s concept of “technological momentum” explains the final stage. Once established, technological systems gain increasing influence over society. A mature technological system resists dismantling because it embeds infrastructure, knowledge, organizational ties, and future expectations.

By 1990, the Soviet recombinant interferon system had acquired many of these traits. It possessed research institutions, industrial facilities, specialised personnel, fermentation infrastructure, pharmaceutical organisations, and interinstitutional relationships. Its existence had created expectations about future production and technological development.

But technological momentum did not make the system immune to political transformation. The dissolution of the USSR in 1991 radically altered the institutional environment in which Soviet biotechnology operated. Unified facilities fractured across new nations. Facilities in Russia, Ukraine, Lithuania, and other former Soviet republics entered different political and economic systems. Funding structures changed, industrial supply chains were disrupted, and institutions that had once been components of a single technological system no longer necessarily belonged to the same political order.

This is one of the most revealing aspects of the Reaferon story. The collapse of the Soviet Union did not erase the technological system overnight. Its physical infrastructure, scientific knowledge, trained personnel, and institutional memory persisted. The system therefore survived in fragmented forms even as the political structure that had originally coordinated it disappeared.

The history of recombinant interferon consequently demonstrates both the strength and the fragility of Soviet technological organisation. The Soviet state had demonstrated an extraordinary capacity to construct a complex biotechnology system by connecting research institutes, industrial organisations, medical institutions, and state agencies. Yet the system’s dependence upon centralised institutional coordination also left it vulnerable to political disintegration.

Before recombinant technology, Soviet interferon relied on donated human blood. This imposed fundamental limitations. Donor availability limited production, while purification, standardization, safety, and scaling posed severe challenges.

Recombinant technology potentially transformed this situation by changing the relationship between biological information and pharmaceutical production. Instead of obtaining interferon directly from human biological material, scientists could reproduce the relevant genetic information and employ microorganisms as production systems.

The shift highlights the program’s wider historical significance. Its importance was not exhausted by the creation of Reaferon. The program laid the technical and organizational groundwork for future post-Soviet recombinant biopharmaceuticals.

From a Hughesian perspective, the most important legacy was therefore not simply the pharmaceutical itself but the “technological system built around it.” The programme produced scientific knowledge, but it also produced institutions capable of applying that knowledge. It developed specialised personnel, production technologies, fermentation capacity, pharmaceutical procedures, and organisational relationships. These components could outlast the political system that built them.

At the same time, the history warns against interpreting Soviet biotechnology as an uncomplicated success story. The programme repeatedly encountered reverse salients. Gene assembly didn’t ensure high yields. High production yields did not guarantee stable industrial production. Industrial production did not automatically guarantee pharmaceutical standardisation. Experimental success did not necessarily translate into routine manufacturing.

The striking discrepancy between Sverdlov’s 1984 production claim and the much lower Ladyzhyn output reported several years later illustrates this problem precisely. Soviet scientists could demonstrate technological capabilities that the larger system struggled to reproduce consistently. The distinction between “demonstration and stabilization” therefore lies at the heart of the history.

The Soviet recombinant interferon programme is best understood not simply as a scientific breakthrough but as an attempt to construct a large technological system around a new form of biotechnology. Beginning in 1979, the programme progressively connected molecular biology, chemical synthesis, genetic engineering, industrial microbiology, fermentation technology, pharmaceutical production, medical research, clinical testing, and state administration. Synthesizing a gene in the early 1980s was a key breakthrough, yet only part of a broader system.

Hughes’s system concept illuminates the program’s institutional complexity. The programme required “system builders” such as Ovchinnikov, who could connect otherwise separated institutions and mobilise political and scientific resources. It required linking diverse components—from research institutes and factories to fermenters and processing facilities. And as the programme expanded, it repeatedly encountered “reverse salients” that had to be overcome before the technology could advance to the next stage.

Reaferon exposes a paradox in late Soviet science. The Soviet system possessed considerable capacity for technological mobilisation. Under favourable political circumstances, it could coordinate institutions that normally operated separately and direct them toward a common strategic objective. Yet biotechnology’s complexity prevented breakthroughs from ensuring stable industrial production. The gap between Sverdlov’s five-million-dose peak and Ladyzhyn’s modest output highlights the divide between proving a technology works and scaling it reliably.

By 1990, Vilnius producing one million doses signaled high technological integration. Yet this achievement occurred at the threshold of the Soviet Union’s dissolution. Political upheaval fractured the institutional structure, while its knowledge, infrastructure, and personnel survived.

The history of Soviet recombinant interferon is therefore ultimately a history of “system building under conditions of political centralisation and technological complexity.” Reaferon emerged from a network assembled to turn genetic code into industrial drugs. Its historical significance lies precisely in this process. The recombinant interferon program proved Soviet science could bridge basic research and industrial biotech, even as it exposed the severe difficulties of maintaining such a system.

Thus, the program’s vital achievement was not the synthetic gene itself. It was building the technological infrastructure required to make that gene matter.

References

  • Pravda. (1987, March). [Report on interferon production at the Ladyzhyn Enzyme Preparations Plant].
  • Reaferon: Conference proceedings, Kol’tsovo, 25–29 January 1993. (1993).
  • Amann, R., & Cooper, J. M. (Eds.). (1982). Industrial innovation in the Soviet Union. Yale University Press.
  • Amann, R., Cooper, J. M., & Davies, R. W. (Eds.). (1977). The technological level of Soviet industry. Yale University Press.
  • Goeddel, D. V., Yelverton, E., Ullrich, A., et al. (1980). Human leukocyte interferon produced by E. coli is biologically active. Nature, 287, 411–416.
  • Graham, L. R. (1993). Science in Russia and the Soviet Union: A short history. Cambridge University Press.
  • Hughes, T. P. (1976). The development phase of technological change. Technology and Culture, 17(3), 423–431.
  • Hughes, T. P. (1983). Networks of power: Electrification in Western society, 1880–1930. Johns Hopkins University Press.
  • Hughes, T. P. (1986). The seamless web: Technology, science, etcetera, etcetera. Social Studies of Science, 16(2), 281–292.
  • Hughes, T. P. (1987). The evolution of large technological systems. In W. E. Bijker, T. P. Hughes, & T. J. Pinch (Eds.), The social construction of technological systems: New directions in the sociology and history of technology (pp. 51–82). MIT Press.
  • Josephson, P. R. (1996). New Atlantis revisited: Akademgorodok, the Siberian city of science. Princeton University Press.
  • Kolosov, M. N., et al. (1983). [Report on the construction of an artificial alpha-2 interferon gene]. Vestnik Akademii Nauk SSSR, (7), 35–41.
  • Nagata, S., Taira, H., Hall, A., Johnsrud, L., Streuli, M., Ecsödi, J., Boll, W., Cantell, K., & Weissmann, C. (1980). Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature, 284, 316–320.
  • Ovchinnikov, Y. A. (1982). Biotechnology and its place in scientific and technological progress. Vestnik Akademii Nauk SSSR, 4, 4–17.
  • Pestka, S. (1983). The interferons: An overview. Methods in Enzymology, 78, 3–14.
  • Rimmington, A. (1988). Biotechnology in the USSR [Doctoral dissertation, University of Birmingham].
  • Rimmington, A. (1992). Technology and transition: A survey of biotechnology in Russia, Ukraine and the Baltic States. Quorum Books.
  • Sverdlov, E. D. (1984, January 10). [Report on recombinant interferon production]. Izvestiya, (10).
  • Zilinskas, R. (1984). Biotechnology in the U.S.S.R., Part 1. Bio/Technology, 2, 610–615.
  • Zilinskas, R. (1984). Biotechnology in the U.S.S.R., Part 2. Bio/Technology, 2, 686–692.